Novel Therapies

The initial clinical trial led to a surprising observation: some patients responded to treatment even at a very low dose.

More uses for MS drug Ozanimod, TSRI study suggests

From left, Hugh Rosen, Michael Oldstone and John Teijaro led the study on previously undiscovered effects of S1P1 agonists.
More uses for MS drug ozanimod, TSRI study suggests. Discovered at TSRI, ozanimod may help with other autoimmune diseases by quelling…

Researchers have found that ‘microvesicles’ – tiny particles released by cells – can penetrate human cartilage, a discovery that could lead to new treatments for arthritis.

Apart from the development of new drugs which can target diseases more specifically and effectively, or the repurposing of old drugs to do the same more safely, targeting can also be achieved through tweaking the delivery system.

A new study could change the way researchers understand and treat autoimmune diseases such as type 1 diabetes, multiple sclerosis and rheumatoid arthritis.

As in cancer therapy, we would like targeted therapies to reach and single out only the bad cells for destruction, without causing collateral damage.
This article is low on specifics, but from what I can gather, nanoparticles are coated with the putative antigen implicated in the particular autoimmune disease to act as bait, zoom in to the responding/reacting activated immune cells, and then release the active compound of the nanoparticles to either destroy or “retrain” the rogue cells.